Compugen (NASDAQ:CGEN) Stock Passes Above 200 Day Moving Average of $1.63

Shares of Compugen Ltd. (NASDAQ:CGEN - Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.63 and traded as high as $2.25. Compugen shares last traded at $2.13, with a volume of 388,383 shares trading hands.

Analysts Set New Price Targets

CGEN has been the subject of a number of recent research reports. Stifel Nicolaus increased their price objective on shares of Compugen from $3.00 to $4.00 and gave the stock a "buy" rating in a research note on Tuesday, December 19th. StockNews.com upgraded Compugen from a "hold" rating to a "buy" rating in a research note on Wednesday, March 6th.

Compugen Stock Down 5.8 %

The business's 50 day simple moving average is $2.48 and its 200 day simple moving average is $1.64. The stock has a market cap of $184.50 million, a price-to-earnings ratio of -9.68 and a beta of 2.63.

Compugen (NASDAQ:CGEN - Get Free Report) last issued its earnings results on Tuesday, March 5th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. The firm had revenue of $33.46 million during the quarter, compared to analyst estimates of $60.00 million. Equities research analysts forecast that Compugen Ltd. will post 0.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mariner LLC boosted its position in Compugen by 207.3% during the fourth quarter. Mariner LLC now owns 36,831 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 24,844 shares during the period. Virtu Financial LLC bought a new stake in shares of Compugen during the 1st quarter worth about $37,000. Envestnet Asset Management Inc. boosted its holdings in shares of Compugen by 68.1% during the 2nd quarter. Envestnet Asset Management Inc. now owns 35,536 shares of the biotechnology company's stock worth $40,000 after buying an additional 14,393 shares during the period. Janney Montgomery Scott LLC grew its stake in Compugen by 58.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 21,700 shares of the biotechnology company's stock valued at $43,000 after buying an additional 8,000 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Compugen by 49.4% in the 2nd quarter. Geode Capital Management LLC now owns 40,579 shares of the biotechnology company's stock valued at $46,000 after acquiring an additional 13,409 shares during the period. 12.22% of the stock is currently owned by institutional investors.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.